A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer

Gerald Schmid-Bindert,Walburga Engel-Riedel,Martin Reck,Wolfgang Schuette, Jan Stöhlmacher,Jürgen R. Fischer,Julien Mazières,Christos Chouaid,Martin Wolf,Nuria Vinolas,Victoria Soldatenkova,Veronique Ripoche,Tuan Nguyen,Carla Visseren-Grul

Lung Cancer（2015）

引用 14|浏览14

暂无评分

摘要

•Feasibility of adjuvant cisplatin or carboplatin+pemetrexed in Stage IB/II NSCLC.•Feasibility definition based on safety, tolerability, and dose-intensity parameters.•Neither treatment met the pre-defined feasibility level >60% of patients.•Feasibility >81% (both treatments) in a post-hoc analysis considering only safety.•Both treatments showed good safety-related feasibility and tolerability.

查看译文

关键词

AE,CTCAE,CI,DFS,IHC,i.v.,MedDRA,NSCLC,OS,SAE,SNP,TEAE,TREAT

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要